Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fenofibrate + vitamin E is a fixed-dose combination of two agents used primarily for their complementary effects on lipid metabolism and oxidative stress. Fenofibrate is a fibrate class drug that acts as an agonist of peroxisome proliferator activated receptor alpha (PPARα), leading to increased lipolysis, reduced triglycerides, decreased LDL cholesterol, and increased HDL cholesterol. Vitamin E (alpha-tocopherol) is a fat-soluble antioxidant that protects cell membranes from oxidative damage by neutralizing free radicals. The combination has been studied for its potential synergistic effect in increasing resistance of non-HDL lipoproteins to oxidation and improving lipid profiles in patients with dyslipidemia or diabetes[1][3]. This combination may be formulated as co-micronized particles for enhanced bioavailability[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fenofibrate + vitamin E.